| Myc depletion induces a pluripotent dormant state mimicking diapause R Scognamiglio, N Cabezas-Wallscheid, MC Thier, S Altamura, A Reyes, ... Cell 164 (4), 668-680, 2016 | 265 | 2016 |
| S6K1 plays a critical role in early adipocyte differentiation LS Carnevalli, K Masuda, F Frigerio, O Le Bacquer, SH Um, V Gandin, ... Developmental cell 18 (5), 763-774, 2010 | 234 | 2010 |
| Combined inhibition of mTOR and CDK4/6 is required for optimal blockade of E2F function and long-term growth inhibition in estrogen receptor–positive breast cancer C Michaloglou, C Crafter, R Siersbaek, O Delpuech, JO Curwen, ... Molecular cancer therapeutics 17 (5), 908-920, 2018 | 157 | 2018 |
| mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma HE Thomas, CA Mercer, LS Carnevalli, J Park, JB Andersen, EA Conner, ... Science translational medicine 4 (139), 139ra84-139ra84, 2012 | 108 | 2012 |
| Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery MA Taylor, AM Hughes, J Walton, AML Coenen-Stass, L Magiera, ... Journal for immunotherapy of cancer 7, 1-16, 2019 | 87 | 2019 |
| PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity LS Carnevalli, C Sinclair, MA Taylor, PM Gutierrez, S Langdon, ... Journal for immunotherapy of cancer 6 (1), 158, 2018 | 79 | 2018 |
| Translation initiation at non-AUG codons mediated by weakened association of eukaryotic initiation factor (eIF) 2 subunits NN Hashimoto, LS Carnevalli, BA Castilho Biochemical Journal 367 (2), 359-368, 2002 | 64 | 2002 |
| Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer A Revenko, LS Carnevalli, C Sinclair, B Johnson, A Peter, M Taylor, ... Journal for Immunotherapy of Cancer 10 (4), 2022 | 51 | 2022 |
| Functional significance of co-occurring mutations in PIK3CA and MAP3K1 in breast cancer A Avivar-Valderas, R McEwen, A Taheri-Ghahfarokhi, LS Carnevalli, ... Oncotarget 9 (30), 21444, 2018 | 51 | 2018 |
| Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity S Langdon, A Hughes, MA Taylor, EA Kuczynski, DA Mele, O Delpuech, ... Oncoimmunology 7 (8), e1458810, 2018 | 50 | 2018 |
| Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response D Georgopoulou, M Callari, OM Rueda, A Shea, A Martin, A Giovannetti, ... Nature communications 12 (1), 1998, 2021 | 45 | 2021 |
| STAT3 Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1 TA Proia, M Singh, R Woessner, L Carnevalli, G Bommakanti, L Magiera, ... Clinical Cancer Research 26 (23), 6335-6349, 2020 | 42 | 2020 |
| Phosphorylation of the α subunit of translation initiation factor-2 by PKR mediates protein synthesis inhibition in the mouse brain during status epilepticus LS Carnevalli, CM Pereira, CB Jaqueta, VS Alves, VN Paiva, KM Vattem, ... Biochemical Journal 397 (1), 187-194, 2006 | 36 | 2006 |
| Improved HSC reconstitution and protection from inflammatory stress and chemotherapy in mice lacking granzyme B LS Carnevalli, R Scognamiglio, N Cabezas-Wallscheid, S Rahmig, ... Journal of Experimental Medicine 211 (5), 769-779, 2014 | 29 | 2014 |
| Phosphorylation of translation initiation factor eIF2α in the brain during pilocarpine-induced status epilepticus in mice LS Carnevalli, CM Pereira, BM Longo, CB Jaqueta, M Avedissian, ... Neuroscience letters 357 (3), 191-194, 2004 | 26 | 2004 |
| Metabolic control by S6 kinases depends on dietary lipids TR Castañeda, W Abplanalp, SH Um, PT Pfluger, B Schrott, K Brown, ... PLoS One 7 (3), e32631, 2012 | 24 | 2012 |
| Clonal somatic copy number altered driver events inform drug sensitivity in high-grade serous ovarian cancer FC Martins, DL Couturier, I De Santiago, CM Sauer, M Vias, M Angelova, ... Nature Communications 13 (1), 6360, 2022 | 20 | 2022 |
| The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and … M Lawson, N Cureton, S Ros, A Cheraghchi-Bashi, J Urosevic, S D'Arcy, ... Cancer Research 83 (23), 3989-4004, 2023 | 19 | 2023 |
| Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer A Harrod, CF Lai, I Goldsbrough, GM Simmons, N Oppermans, DB Santos, ... Oncogene 41 (44), 4905-4915, 2022 | 19 | 2022 |
| Dissecting the early steps of MLL induced leukaemogenic transformation using a mouse model of AML S Basilico, X Wang, A Kennedy, K Tzelepis, G Giotopoulos, SJ Kinston, ... Nature Communications 11 (1), 1407, 2020 | 18 | 2020 |
